These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32499107)

  • 1. Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan.
    Cheng PN; Chen CY; Yu ML; Lin CC; Lin CY; Peng CY; Tseng KC; Lo CC; Tseng IH; Liu CJ
    J Microbiol Immunol Infect; 2021 Aug; 54(4):588-595. PubMed ID: 32499107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis.
    Liu CH; Peng CY; Fang YJ; Kao WY; Yang SS; Lin CK; Lai HC; Su WP; Fang SU; Chang CC; Su TH; Liu CJ; Chen PJ; Chen DS; Kao JH
    Sci Rep; 2020 Jun; 10(1):9180. PubMed ID: 32513953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of elbasvir/grazoprevir treatment in HCV genotype 1 patients in Taiwan.
    Tsai TC; Deng ST; Hsu CW
    J Med Virol; 2020 Feb; 92(2):219-226. PubMed ID: 31599455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
    Jacobson IM; Lawitz E; Kwo PY; Hézode C; Peng CY; Howe AYM; Hwang P; Wahl J; Robertson M; Barr E; Haber BA
    Gastroenterology; 2017 May; 152(6):1372-1382.e2. PubMed ID: 28193518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection.
    Corman S; Elbasha EH; Michalopoulos SN; Nwankwo C
    Value Health; 2017 Sep; 20(8):1110-1120. PubMed ID: 28964443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, noncirrhotic HCV genotype 3-infected patients.
    Gane E; Nahass R; Luketic V; Asante-Appiah E; Hwang P; Robertson M; Wahl J; Barr E; Haber B
    J Viral Hepat; 2017 Oct; 24(10):895-899. PubMed ID: 28470815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort.
    Hernández-Conde M; Fernández I; Perelló C; Gallego A; Bonacci M; Pascasio JM; Romero-Gómez M; Llerena S; Fernández-Rodríguez C; Castro Urda JL; García Buey L; Carmona I; Morillas RM; García ND; Gea F; Carrión JA; Castellote J; Moreno-Planas JM; Piqueras Alcol B; Molina E; Diago M; Montoliu S; de la Vega J; Menéndez F; Sánchez Ruano JJ; García-Samaniego J; Rosales-Zabal JM; Anton MD; Badia E; Souto-Rodríguez R; Salmeron FJ; Fernández-Bermejo M; Figueruela B; Moreno-Palomares JJ; Calleja JL
    J Viral Hepat; 2019 Jan; 26(1):55-64. PubMed ID: 30265418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study.
    Kumada H; Suzuki Y; Karino Y; Chayama K; Kawada N; Okanoue T; Itoh Y; Mochida S; Toyoda H; Yoshiji H; Takaki S; Yatsuzuka N; Yodoya E; Iwasa T; Fujimoto G; Robertson MN; Black S; Caro L; Wahl J
    J Gastroenterol; 2017 Apr; 52(4):520-533. PubMed ID: 27873094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials.
    Zamor PJ; Vierling J; Ghalib R; Luketic V; Ravendhran N; Balart L; Robertson M; Hwang P; Hanna GJ; Nguyen BY; Barr E; Talwani R; Pearlman B
    Am J Gastroenterol; 2018 Jun; 113(6):863-871. PubMed ID: 29695828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study.
    Brown A; Hézode C; Zuckerman E; Foster GR; Zekry A; Roberts SK; Lahser F; Durkan C; Badshah C; Zhang B; Robertson M; Wahl J; Barr E; Haber B;
    J Viral Hepat; 2018 May; 25(5):457-464. PubMed ID: 29152828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.
    Foster GR; Agarwal K; Cramp ME; Moreea S; Barclay S; Collier J; Brown AS; Ryder SD; Ustianowski A; Forton DM; Fox R; Gordon F; Rosenberg WM; Mutimer DJ; Du J; Gilbert CL; Asante-Appiah E; Wahl J; Robertson MN; Barr E; Haber B
    Hepatology; 2018 Jun; 67(6):2113-2126. PubMed ID: 29473975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection.
    Lee YJ; Heo J; Kim DY; Chung WJ; Tak WY; Kim YJ; Paik SW; Sim E; Kulasingam S; Talwani R; Haber B; Hwang P
    Clin Mol Hepatol; 2019 Dec; 25(4):400-407. PubMed ID: 31132846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease.
    Ogawa E; Furusyo N; Azuma K; Nakamuta M; Nomura H; Dohmen K; Satoh T; Kawano A; Koyanagi T; Ooho A; Takahashi K; Kato M; Shimoda S; Kajiwara E; Hayashi J;
    Antiviral Res; 2018 Nov; 159():143-152. PubMed ID: 30300717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population.
    Choi DT; Puenpatom A; Yu X; Erickson KF; Kanwal F; El-Serag HB; Kramer JR
    Antiviral Res; 2020 Feb; 174():104698. PubMed ID: 31862503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system.
    Kramer JR; Puenpatom A; Erickson KF; Cao Y; Smith D; El-Serag HB; Kanwal F
    J Viral Hepat; 2018 Nov; 25(11):1270-1279. PubMed ID: 29851265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.
    Kwo P; Gane EJ; Peng CY; Pearlman B; Vierling JM; Serfaty L; Buti M; Shafran S; Stryszak P; Lin L; Gress J; Black S; Dutko FJ; Robertson M; Wahl J; Lupinacci L; Barr E; Haber B
    Gastroenterology; 2017 Jan; 152(1):164-175.e4. PubMed ID: 27720838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network.
    Flamm SL; Bacon B; Curry MP; Milligan S; Nwankwo CU; Tsai N; Younossi Z; Afdhal N
    Aliment Pharmacol Ther; 2018 Jun; 47(11):1511-1522. PubMed ID: 29665097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients.
    Ji Q; Chu X; Zhou Y; Liu X; Zhao W; Ye W
    J Med Virol; 2022 Feb; 94(2):675-682. PubMed ID: 34599755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial.
    Sperl J; Horvath G; Halota W; Ruiz-Tapiador JA; Streinu-Cercel A; Jancoriene L; Werling K; Kileng H; Koklu S; Gerstoft J; Urbanek P; Flisiak R; Leiva R; Kazenaite E; Prinzing R; Patel S; Qiu J; Asante-Appiah E; Wahl J; Nguyen BY; Barr E; Platt HL
    J Hepatol; 2016 Dec; 65(6):1112-1119. PubMed ID: 27542322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elbasvir and grazoprevir for the treatment of hepatitis C.
    Wang SJ; Huang CF; Yu ML
    Expert Rev Anti Infect Ther; 2021 Sep; 19(9):1071-1081. PubMed ID: 33428488
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.